SecBot SecBot

KOD drug pipeline

Kodiak Sciences Inc. · 3 rated drugs
$111.19
+2.7% 1-day · Nov 13
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
±62.6%
1-day, median of 1 event
IV rank
No data
No current options data
Rated drugs
3
2 bullish · 1 neutral
Phase 3 trials
2
0 with results posted

Drugs

soonest catalyst first
▲ bullish
Impact
PhasePhase 3
Time to marketIf Phase 3 PEAK succeeds, a BLA submission would follow. The company expects Pivotal Analysis 2 data in Q2 2027, suggesting a potential BLA filing in 2027 and potential approval in 2028, though no official timeline has been given.

KSI-101 Updated Nov 13

What to watch

The December 2026 PEAK topline data is the key binary event to watch. If KSI-101 replicates the Phase 1b APEX signal (meaningful vision gains, rapid retinal drying) in the larger Phase 3 setting, it would validate the bispecific IL-6/VEGF approach and strengthen Kodiak's pipeline beyond Zenkuda. A miss or underwhelming result would be a significant negative given the elevated stock price and stretched cash position. The company's thin equity base ($12.6 million) and ~$66 million quarterly burn rate mean financing risk is high regardless of the readout outcome.

Bull case
  • Phase 1b APEX data showed strong results: meaningful vision gains as early as week 4, over 90% of patients achieving absence of macular edema, and more than half of patients in top dose levels gaining 15+ letters (3 lines) on the eye chart after a single dose (source: Kodiak press release, September 2025)
  • The company's platform and retinal disease expertise were validated by the September 2026 DAYBREAK Phase 3 success for Zenkuda and KSI-501, which de-risks the broader pipeline including KSI-101 (source: Kodiak 8-K filed November 12, 2026)
  • Baker Bros. Advisors, a 10% owner and director, made large open-market purchases of roughly $24 million in early November 2026 at ~$98.51/share, signaling insider confidence ahead of the December readout
Bear case
  • Cash burn is severe: Q3 2026 net loss was $66.2 million, and cash dropped to $88.7 million at quarter-end (plus $69 million raised post-quarter via ATM). Stockholders' equity was only $12.6 million, raising going-concern risk if additional financing is not secured (source: Kodiak 10-Q filed November 12, 2026, and 8-K analysis)
  • The stock already trades at a ~$6.8 billion market cap after the 178% DAYBREAK surge, embedding optimistic assumptions. A Seeking Alpha analyst (November 13, 2026) argues the valuation already prices in Zenkuda success and that more financing is likely (source: Seeking Alpha, November 13, 2026)
  • Competition is emerging: Genentech/Roche is developing vamikibart for uveitic macular edema, with positive Phase III MEERKAT and SANDCAT data presented in October 2026 (source: Genentech press release via marketscreener, October 2026)
▲ bullish
Impact
PhasePhase 3 (completed)
Time to marketBLA submission planned for Q4 2026. If accepted and standard review, a PDUFA decision would likely ~6 months after submission, putting a potential approval in mid-2027.

tarcocimab tedromer Updated Oct 24

What to watch

Watch for the BLA submission for Zenkuda in Q4 2026, the exact filing date and whether it covers wet AMD and/or diabetic retinopathy will be key. Monitor ATM sales pace via quarterly filings for dilution pressure. The next binary event after submission will be the PDUFA date assignment and eventual FDA decision (~6 months post-submission, likely mid-2027).

Bull case
  • Five positive Phase 3 studies across wet AMD, diabetic retinopathy, and RVO, a rare clean sweep that de-risks the clinical package ahead of BLA submission (source: Kodiak pipeline page, https://kodiak.com/our-pipeline/)
  • 6-month dosing durability is a major competitive advantage vs. current standard of care (Eylea at 1-2 months, Vabysmo at 2-4 months), which could drive strong adoption by reducing treatment burden on patients and clinics
  • Stock surged ~178% on DAYBREAK data and ~63% on GLOW2 BLA announcement, showing the market sees huge value; analyst consensus is Strong Buy with mean price target of $121.67, implying ~39% upside from $87.63
Bear case
  • $350M ATM equity shelf filed October 2026 with J.P. Morgan, up to $350M in potential dilution; CFO Borgeson sold ~$30K+ shares via 10b5-1 plan at $87-94/share in October 2026 (source: SEC S-3ASR filing analysis, https://www.sec.gov/Archives/edgar/data/1468748/000119312526426854/0001193125-26-426854-index.htm)
  • Pre-revenue biotech with $125.9M cash burning ~$84M per half, likely needs additional financing before commercialization even after the ATM (source: Q2 2026 8-K filing analysis, https://www.sec.gov/Archives/edgar/data/1468748/000119312526349107/0001193125-26-349107-index.htm)
  • Intense competition from established anti-VEGF blockbusters: Regeneron's Eylea (~$6B/year), Roche's Vabysmo (~~$4B/year, Novartis's Beovu, and upcoming next-gen therapies from other companies
● neutral
Impact
PhasePhase 3
Time to marketUnknown — DAYBREAK Phase 3 readout is positive, but Tabirafusp (KSI-501) still requires regulatory review and a separate Phase 3 ALTO study in DME. If prioritized, potential approval could be 2-3+ years out.

Tabirafusp alfa tedromer Updated Oct 24

What to watch

The DAYBREAK Phase 3 readout (Sept 28, 2026) was the defining binary catalyst for Tabirafusp, it was a clear success, driving the stock from ~$32 to ~$90. The next catalysts are the PEAK Phase 3 readout for KSI-101 (Dec 2026) and the Zenkuda BLA submission (Q4 2026), but these are separate pipeline assets. For Tabirafusp specifically, watch for the ALTO Phase 3 study in DME and any regulatory path updates. The stock now trades near analyst targets ($103-$145 range) with ~39% implied upside to the mean target of $122.

Bull case
  • DAYBREAK Phase 3 results (Sept 28, 2026) were strongly positive, the stock opened at $61.70 from a ~$32 close, hitting $95.83 intraday on 38.5M shares volume, suggesting strong efficacy vs aflibercept in wet AMD.
  • Analyst consensus is strongly bullish: 9 of 9 analysts rate Buy/Strong Buy, with a mean price target of $121.67 (high $145, low $103), implying ~39% upside from $87.63.
  • Baker Bros. Advisors bought heavily into the DAYBREAK readout, purchasing ~$30M+ in stock on Sept 28-29 at $84-$90, signaling strong informed conviction.
Bear case
  • The DAYBREAK readout is already priced in, the stock surged from ~$32 to ~$90 on Sept 28, leaving limited upside from here unless follow-on data surprises positively.
  • Kodiak has no approved products and an accumulated deficit of ~$1.68B. Cash of $125.9M (June 30, 2026) is burning at ~$42M/quarter, likely requiring dilutive financing before reaching profitability.
  • The company filed an S-3ASR shelf and an ATM agreement for up to $350M in stock sales (Oct 20, 2026), creating persistent dilution overhang.

Other drugs in filings and trials

no drug report yet

Past FDA events & how the stock moved

1 events
DateDrugEvent1 day5 days
Mar 26, 2026tarcocimab tedromerBLA filed+62.6%+78.6%

Clinical trials

2 Phase 2/3
DrugTrialPhaseStatusEnrolledPrimary completion
tarcocimab tedromerA Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) - DAYBREAKPhase 3Active not recruiting675Aug 2026
TarcocimabA Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer Compared With Sham Treatment in Participants With Diabetic Retinopathy (DR)Phase 3Completed255Feb 13, 2026